The use of fluoroquinolones in gonorrhoea: The increasing problem of resistance

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 4, 2004, Pages 829-854

  Dan, Michael ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Ciprofloxacin; DNA gyrase; DNA topoisomerase; Drug resistance; Fluoroquinolones; Gonorrhoea; Neisseria gonorrhoeae

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DIFLOXACIN; DOXYCYCLINE; ENOXACIN; FLEROXACIN; GREPAFLOXACIN; KANAMYCIN; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; PENICILLINASE; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SPECTINOMYCIN; SULFONAMIDE; TEMAFLOXACIN; TETRACYCLINE; THIAMPHENICOL; TROVAFLOXACIN; UNINDEXED DRUG;

AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AUSTRALIA; BACTERIAL STRAIN; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INDICATION; ENZYME SYNTHESIS; EUROPE; FAR EAST; GONORRHEA; HUMAN; NEISSERIA GONORRHOEAE; PREVALENCE; REVIEW; SOUTH AND CENTRAL AMERICA; UNITED STATES;

CLINICAL TRIALS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE;

EID: 1842832773     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.4.829     Document Type: Review

References (232)

1. DONOVAN B, BODSWORTH NJ, ROHRSHEIM R, MCNULTY A, TAPSALL JW: Increasing gonorrhoea reports - not only in London. Lancet (2000) 355:1908.
2. BERGLUND T, FREDLUND H, GIASCKE J: Epidemiology of the re-emergence of gonorrhea in Sweden. Sex. Transm. Dis. (2001) 28:111-114.
3. MARTIN IMC, ISON CA: Rise in gonorrhoea in London, UK. Lancet (2000) 355:623.
4. GOULET V, SEDNAOUI P, LAPORTE A, BILLY C, DESENCLOS JC: The number of gonococcal infections identified by the RENACO network is increasing. Eurosurveillance (2000) 5:2-5.
5. SERWAL S, WONG T, SEVIGNY C, NG L-K: Increasing frequency of ciprofloxacin-resistant N. gonorrhoeae infection in Canada. J. Can. Med. Assoc. (2003) 169:872-873.
6. CENTERS FOR DISEASE CONTROL AND PREVENTION: Sexually Transmitted Diseases Surveillance, 2002. Atlanta, GA: US Department of Health and Human Services, September 2003.
7. LIND I: Antimicrobial resistance in Neisseria gonorrhoeae. Clin. Infect. Dis. (1997) 24(Suppl. 1):S93-S97.
8. ISON CA, DILLON J-AR, TAPSALL JW: The epidemiology of global antibiotic resistance among Neisseria gonorrhoeae and Hemophilus ducreyi. Lancet (1998) 351:8-11.
9. ERBELDING E, QUINN TC: The impact of antimicrobial resistance on the treatment of sexually transmitted diseases. Infect. Dis. Clin. N. Am. (1997) 4:889-903.
10. MURATANI T, KOBAYASHI T, OSHI M et al.: The susceptibility of gonococcal isolates to penicillins, cephems, quinolones, tetracyclines, and spectinomycin in various area of Japan in 2002. Program and abstracts of the 15th Annual Meeting of the International Society of Sexually Transmitted Disease Research, Ottawa, Ontario, Canada. July 27 - 30 (2003) (Abstract 375).
11. CENTERS FOR DISEASE CONTROL AND PREVENTION: 1998 Sexually transmitted diseases treatment guidelines. Morb. Mortal. Wkly. Rep. (1998) 38:S8.
12. PEELING RW, RONALD AR: Use of quinolones in sexually transmitted diseases. In: Quinolones Antimicrobial Agents (2nd edn). Hooper DC, Wolfson JS (Eds), American Society for Microbiology, Washington, DC, USA (1993):299-327.
13. WANG JC: DNA topoisomerases. Ann. Rev. Biochem. (1996) 65:635-692.
14. BELLAND RJ, MORRISON SG, ISON C, HUANG WM: Neisseria gonorrhoeae acquired mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol. Microbiol. (1994) 14:371-380.
15. ULLSPERGER C, COZZARELLI NR: Contrasting enzymatic activity of topoisomerase IV and DNA gyrase from Escherichia coli. J. Biol. Chem. (1996) 271:31549-31555.
16. SHULTZ TR, TAPSALL JW, WHITE PA: Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Antimicrob. Agents Chemother. (2001) 45:734-738.
17. CHEN LL, KOHLBRENNER WE, WEIGL D, BARANOWSKI J: Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J. Biol. Chem. (1989) 264:2973-2978.
18. ECHLOS RM, HEYD A, O'KEEFFE BJ, SCHACHT P: Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: A worldwide summary. Sex Transm. Dis. (1994) 21:345-352.
19. PHANUCHARAS JP, GORBY GL: Differential intracellular efficacies of ciprofloxacin and cefixime against Neisseria gonorrhoeae in human fallopian tube organ culture. Antimicrob. Agents Chemother. (1997) 41:1547-1551.
20. TAPSALL J: Current concepts in the management of gonorrhea. Expert Opin. Pharmacother. (2002) 3:147-157.
21. MORAN JS, LEVINE WC: Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin. Infect. Dis. (1995) 20(suppl 1);S47-S65.
22. CENTERS FOR DISEASE CONTROL 1989 Sexually transmitted diseases treatment guidelines. Morb. Mortal. Wkly Rep. (1989) 38:21-27.
23. CENTERS FOR DISEASE CONTROL: 1993 Sexually transmitted diseases treatment guidelines. Morb. Mortal. Wkly Rep. (1993) 42:56-62.
24. GRANSDEN WR, WARREN CA, PHILLIPS I, HODGES M, BARLOW D: Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet (1990) 335:51.
25. JEPHCOTT AE, TURNER A: Ciprofloxacin resistance in gonococci. Lancet (1990) 335:165.
26. BIRLEY H, MCDONALD P, CAREY P, FLETCHER J: High level ciprofloxacin resistance in Neisseria gonorrhoeae. Genitourin. Med. (1994) 70:292-293.
27. GRANSDEN WR, WARREN C, PHILLIPS I: 4-Fluoroquinolone-resistant Neisseria gonorrhoeae in the United Kingdom. J. Med. Microbiol. (1991) 34:23-27.
28. CORKILL JE, PERCIVAL A, LIND M: Reduced uptake of ciprofloxacin in a resistant strain of N. gonorrhoeae and transformation of resistance to other strains. J. Antimicrob. Chemother. (1991) 28:601-604.
29. TAPSALL JW, LOVETT R, MUNRO R: Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhea. Med. J. Aust. (1992) 156:143.
30. CENTERS FOR DISEASE CONTROL AND PREVENTION: Fluoroquinolones resistance in Neisseria gonorrhoeae - Colorado and Washington, 1995. Morb. Mortal. Wkly Rep. (1995) 44:761-764.
31. KAM KM, WONG PW, CHEUNG MM, HO NKY: Detection of fluoroquinolone-resistant Neisseria gonorrhoeae. J. Clin. Microbiol. (1996) 34:1462-1464.
32. RINGUETTE L, TRUDEAU T, TURCOTTE T et al.: Emergence of Neisseria gonorrhoeae strains with decreased susceptibility to ciprofloxacin - Quebec, 1994 - 1995. Can. Commun. Dis. Rep. (1996) 22:121-125.
33. TURNER A, GOUGH KR, JEPHCOTT AE, MCLEAN AN: Importation into the UK of a strain of Neisseria gonorrhoeae resistant to penicillin, ciprofloxacin and tetracycline. Genitourin. Med. (1995) 71:331-332.
34. TAPSALL JW, PHILLIPS EA, SHULTZ TR, THACKER C: Quinolone-resistant Neisseria gonorrhoeae in Sidney, Australia, 1991 to 1995. Sex. Transm. Dis. (1996) 23:425-428.
35. KNAPP JS, HALE JA, NEAL SW, WINTERSHEID K, RICE RJ, WITTINGTON WI: Proposed criteria for interpretation of susceptibilities to strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin. Antimicrob. Agents Chemother. (1995) 39:2442-2445.
36. KNAPP JS, FOX KK, TREES DL, WHITTINGTON WL: Fluoroquinolones resistance in Neisseria gonorrhoeae. Emerg. Infect. Dis. (1997) 3:33-39.
37. IVENS D, MARTIN I, ISON C: Neisseria gonorrhoeae in a London sexually transmitted infection clinic not fully sensitive to quinolones: are isolates imported and how effective is ciprofloxacin as a firs-line therapy. Int. J. STD AIDS (2000) 11:774-776.
38. ISON CA, WOODFORD PJ, MADDERS H, CLAYTON E: Drift in susceptibility of Neisseria gonorrhoeae to ciprofloxacin and emergence of therapeutic failure. Antimicrob. Agents Chemother. (1998) 42:2919-2922.
39. HANDSFIELD HH, WITTINGTON WL: Antibiotic-resistant Neisseria gonorrhoeae: The calm before another storm. Ann. Intern. Med. (1996) 125:507-509.
40. Annual Report Of The Australian Gonococcal Surveillance Programme 2000: Commun. Dis. Intell. (2001) 25:59-63.
41. FORAYTH A, MOYES A, YOUNG H: Increased ciprofloxacin resistance in gonococci isolated in Scotland. Lancet (2000) 356:1984-1985.
42. COMMUNICABLE DISEASES NETWORK AUSTRALIA: Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2001. Commun. Dis. Intell. (2002) 26:541-545.
43. O'DONNELL JA, GELONE SP: Fluoroquinolones. Infect. Dis. Clin. N. Am. (2000) 14:489-513.
44. HOOPER DC: Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. (2001) 7; 337-341.
45. DEGUCHI T, YASUDA M, NAKANO M et al.: Uncommon occurrence of mutations in the gyrB gene associated with quinolone resistance in clinical isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. (1996) 40:2437-2438.
46. SU X, LIND I: Molecular basis of high-level ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Denmark from 1995 to 1998. Antimicrob. Agents Chemother. (2001) 45:117-123.
47. TANAKA M, MATSUMOTO T, SAKUMOTO M et al.: Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone-resistant isolates with the GyrA mutation. Antimicrob. Agents Chemother. (1998) 42:579-582.
48. NG L-K, SAWATZKY P, MARTIN IE, BOOTH S: Characterization of ciprofloxacin resistance in Neisseria gonorrhoeae isolates in Canada. Sex. Transm. Dis. (2002) 29:780-789.
49. KAM KM, LO KK, LAI CF, LEE YS, CHAN CB: Ofloxacin susceptibilities of 5,667 Neisseria gonorrhoeae strains isolated in Hong Kong. Antimicrob. Agents Chemother. (1993) 37:2007-2008.
50. KAM KM, KAM SS, CHEUNG DT, TUNG VW, AU WF, CHEUNG MM: Molecular characterization of quinolone-resistant Neisseria gonorrhoeae in Hong Kong. Antimicrob. Agents Chemother. (2003) 47:436-439.
51. TREES DL, SANDUL AL, PETO-MESOLA V et al.: Alterations within the quinolone resistance-determining regions of GyrA and ParC of Neisseria gonorrhoeae isolated in the Far East and the United States. Int. J. Antimicrob. Agents (1999) 12:325-332.
52. TANAKA M, NAKAYAMA H, HARAOKA M, SAIKA T, KOBAYASHI I, NAITO S: Antimicrobial resistance of Neisseria, gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993-1998. J. Clin. Microbiol. (2000) 38:521-525.
53. OTERO L, ALCALA B, VARELA JA, MIGUEL MD, VAZQUEZ JA, VAZQUEZ F: The first isolate of a Neisseria gonorrhoeae strain associated with an ofloxacin treatment failure in Spain: Case report. Sex. Transm. Dis. (2001) 28:576-578.
54. LINDBACK E, RAHMAN M, JALAL S, WRETLIND B: Mutations in gyrA, gyrB, parC, and parE in quinolone-resistant strains of Neisseria gonorrhoeae. AMPIS (2002) 110:651-657.
55. TANAKA M, NAKAYAMA H, HARAOKA M, SAIKA T, KOBAYASHI I, NAITO S: Susceptibility of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics. Antimicrob. Agents Chemother. (2000) 44:192-195.
56. TREES DL, SANDUL AL, WHITTINGTON WL, KNAPP JS: Identification of novel mutations patterns in the ParC gene of ciprofloxacin-resistant isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. (1998) 42:2103-2105.
57. DEGUCHI T, YASUDA M, NAKANO M et al.: Quinolone-resistant Neisseria gonorrhoeae: Correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob. Agents Chemother. (1996) 40:1020-1023.
58. TANAKA M, SAKUMA S, TAKAHASHI K et al.: Analysis of quinolone resistance mechanisms in Neisseria gonorrhoeae isolates in vitro. Sex. Transm. Infect. (1998) 74:59-62.
59. MAVROIDI A, TZOUVELEKIS LS, TASSIOS PT, FLEMETAKIS A, DANILIDOU M, TZELEPI E: Characterization of Neisseria gonorrhoeae strains with decreased susceptibility to fluoroquinolones isolated in Greece from 1996 to 1999. J. Clin. Microbiol. (2000) 38:3489-3491.
60. DE NEELING AJ, VAN SENTEN-VERHEUEL M, SRAARGAREN J, WILLEMS RJL: Antimicrobial resistance of Neisseria gonorrhoeae and emerging ciprofloxacin resistance in the Netherlands, 1991-1998. Antimicrob. Agents Chemother. (2000) 44:3184-3185
61. GILES J, YEUNGER J, ZENILMAN J, DAN M, BASH M: Characterization of porin type and QRDR mutation in ciprofloxacin resistant strains of Neisseria gonorrhoeae from Israel. Program and Abstracts of the 15th Annual Meeting of the International Society of Sexually Transmitted Disease Research, Ottawa, Ontario, Canada. July 27 - 30 (2003) Abstract 459.
62. LKHAMSUREN E, SHULTZ TR, LIMNIOS EA, TAPSAL JW: The antibiotic susceptibility of Neisseria gonorrhoeae isolated in Ulaanbaatar, Mongolia. Sex. Transm. Infect. (2001) 77:218-220.
63. TREES DL, SANDUL AL, NEAL SW et al.: Molecular epidemiology of Neisseria gonorrhoeae exhibiting decreased susceptibility and resistance to ciprofloxacin in Hawaii, 1991 - 1999. Sex. Transm. Dis. (2001) 28:309-314.
64. CHAUDHRY U,RAY K, BALA M, SALUJA D: Mutation patterns in gyrA and parC genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India. Sex. Transm. Infect. (2002) 78:440-444.
65. KNAPP JS, MESOLA V, NEAL SW et al.: Molecular epidemiology, in 1994, of Neisseria gonorrhoeae in Manila and Cebu City, Republic of the Philippines. Sex. Transm. Dis. (1997) 24:2-7.
66. KNAPP JS, WONGBA C, LIMPAKARNJANARAT K et al.: Antimicrobial susceptibility of strains of Neisseria gonorrhoeae in Bangkok, Thailand: 1994-1995. Sex. Transm. Dis. (1997) 24:142-148.
67. TREES DL, SIRIVONGRANGSON P, SCHULTZ AJ et al.: Multiclonal increase in ciprofloxacin-resistant Neisseria gonorrhoeae, Thailand, 1998-1999. Sex. Transm. Dis. (2002) 29:668-673.
68. HARNETT N, BROWN S, RILEY G et al.: Analysis of Neisseria gonorrhoeae in Ontario, Canada, with decreased susceptibility to quinolone by pulsed-field gel electrophoresis, auxotyping, serotyping and plasmid content. J. Med. Microbiol. (1997) 46:383-390.
69. GORDON SM, CARLYN CJ, DOYLE LJ et al.: The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: Epidemiology and risk factors. Ann. Intern. Med. (1996) 125:465-470.
70. YAGUPSKY P, SCHAHAR A, PELED N et al.: Increasing incidence of gonorrhea in Israel associated with countrywide dissemination of a ciprofloxacin resistant strain. Eur. J. Clin. Microbiol. Infect. Dis. (2002) 2:268-272.
71. TANAKA M, FUKUDA II, HIRAI K et al.: Reduced uptake and accumulation of norfloxacin in resistant strains of Neisseria gonorrhoeae isolated in Japan. Genitourin. Med. (1994) 70:253-255.
72. HOOPER DC, WOLFSON JS, NG EY et al.: Mechanisms of action and resistance to ciprofloxacin. Am. J. Med. (1987) 82:12-20.
73. DEGUCHI T, SAITO I, TANAKA M et al.: Fluoroquinolone treatment failure in gonorrhea: Emergence of a Neisseria gonorrhoeae strain with enhanced resistance to fluoroquinolones. Sex. Transm. Dis. (1997) 24:247-250
74. TANAKA M, SAKUMA S, TAKAHASHI K et al.: Analysis of quinolone resistance mechanisms in Neisseria gonorrhoeae isolates in vitro. Sex. Transm. Infect. (1998) 74:59-62.
75. WEISFUSE IR: Gonorrhea control and antimicrobial resistance. Lancet (1998) 351:928.
76. KNAPP JS, NEAL SW, PAREKH MC, RICE J: In vitro activity of a new fluoroquinolones, CP-99,219 against strains of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. (1995) 39:987-989.
77. JONES RN, BARRETT MS, DEGUCHI T: Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etast results. Diagn. Microbiol. Infect. Dis. (1997) 28:193-200.
78. JONES RN, DESHPANDE LM, ERWIN ME, BARRETT MS, BEACH ML: Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods. J. Antimicrob. Chemother. (2000) 45(Suppl. 1):67-70.
79. BERRON S, VASQUEZ JA, GIMENEZ MJ, DE LA FUENTE L, AGUILAR L: In vitro susceptibility of 400 Spanish isolates of Neisseria gonorrhoeae to gemifloxacin and 11 other antimicrobial agents. Antimicrob. Agents Chemother. (2000) 44:2543-2544.
80. TANAKA M, TUNOE H, MOCHIDA O et al.: Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolones, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolones-resistant isolates. Diagn. Microbiol. Infect. Dis. (2000) 38:109-113.
81. BIEDENBACH DJ, BEACH ML, JONES RN: Antimicrobial activity of gatifloxacin against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolones-resistant strains. Diagn. Microbiol. Infect. Dis. (1998) 32:307-311.
82. CARLYN CJ, DOYLE LJ, KNAPP CC, LUDWIG MD, WASHINGTON JA: Activities do three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibility to ciprofloxacin and ofloxacin. Antimicrob. Agents Chemother. (1995) 39:1606-1608.
83. KLAUSNER JD, APLASCA M-R, MESOLA VP, BOLAN G, WHITTINGTON WL, HOLMES KK: Correlates of gonococcal infection and of antimicrobial-resistant Neisseria gonorrhoeae among female sex workers, Republic of the Philippines, 1996 - 1997. J. Infect. Dis. (1999) 179:729-733.
84. KNAPP JS, OHYE R, NEAL SW, PAREKH MC, HIGA H, RICE RJ: Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii. Antimicrob. Agents Chemother. (1994)38:2200-2203.
85. TAPSALL JW, SHULTZ TR, PHILLIPS AE: Characteristics of Neisseria gonorrhoeae isolated in Australia showing decreased sensitivity to fluoroquinolone antibiotics. Pathology (Phila) (1992) 24:27-31.
86. BERGLUND T, UNEMO M, OLCEN P, GIESECKE J, FREDLUND H: One year of Neisseria gonorrhoeae isolates in Sweden: The prevalence study of antibiotic susceptibility shows relation to the geographic area of exposure. Int. J. STD AIDS (2002) 13:109-114.
87. TAYAL SC, SANKAR KN, PATTMAN RS, WATSON PG, GALLOWAY A: Neisseria gonorrhoeae in Newcastle upon Tyre 1995 - 1997: Increase in ciprofloxacin resistance. Int. J. STD AIDS (1999) 10:290-293.
88. PATRICK D, SHAW C, REKART ML: Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in British Columbia: An imported phenomenon. Can. Commun. Dis. Rep. (1995) 21:137-139.
89. MACAULAY ME: Acrosoxacin resistance in Neisseria gonorrhoeae. Lancet (1982) 1:171-172.
90. TANAKA M, KUMAZAWA J, MATSUMOTO T, KOBAYASHI I: High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan. Genitourin. Med. (1994) 70:90-93.
91. GRANSDEN WR, WARREN CA, PHILLIPS I, HODGES M, BARLOW D: Decreased susceptibility of Neisseria gonorrhoeae to ciprofloxacin. Lancet (1990) 335:51.
92. WAGENVOORT JHT, VAN DER WILLINGEN AH, VAN VLIET HJ, MICHEL MF, VAN KLIGEREN B: Resistance of Neisseria gonorrhoeae to enoxacin. J. Antimicrob. Chemother. (1986) 18:429.
93. CLENDENNEN TE, HAMES CS, KEES ES et al.: In vitro antibiotic susceptibilities of Neisseria gonorrhoeae isolates in the Philippines. Antimicrob. Agents Chemother. (1992) 36:277-282.
94. YEUNG KH, DILLON JR: Norfloxacin resistant Neisseria gonorrhoeae in North America. Lancet (1990) 336:759.
95. DIVEKAR AA, GOGATE AS, SHIVKAR LK: Association between auxotypes, serogroups, and antibiotic susceptibilities of Neisseria gonorrhoeae isolated from women in Mumbai (bombay), India. Sex. Transm. Dis. (1999) 26(6):358-363.
96. RAY K, BALA M, KUMAR J, MISRA RS: Trend of antimicrobial resistance in N. gonorrhoeae at New Delhi, India. Int. J. STD AIDS (2000) 11:115-118.
97. BALA M, RAY K, KUMARI S: Alarming increase in ciprofloxacin- and penicillin-resistant Neisseria gonorrhoeae isolates in New Delhi, India. Sex. Transm. Dis. (2003) 30:523-525.
98. BHUIYAN BU, RAHMEN M, MIAH RA et al.: Antimicrobial susceptibility and plasmid content of N. gonorrhoeae isolated from commercial sex workers in Dhaka, Bangladesh: Emergence of high level resistance to ciprofloxacin. J. Clin. Microbiol. (1999) 37:1130-1136.
99. RAHMAN M, SULTAN Z, MONIRA S et al.: Antimicrobial susceptibility of Neisseria gonorrhoeae isolated in Bangladesh (1997-1999): Rapid shift to fluoroquinolone resistance. J. Clin. Microbiol. (2002) 40:2037-2040.
100. RAHMAN M, ZAFAR S, MONIRA S et al.: Antimicrobial susceptibility of Neisseria gonorrhoeae isolated from Bangladesh (1997-2002):rApid shift to fluoroquinolone and multidrug resistance. Program and Abstracts of the 15th Annual Meeting of the International Society of Sexually Transmitted Disease Research, Ottawa, Ontario, Canada. July 27 - 30 (2003) Abstract 620.
101. NATIONAL CENTRE FOR DISEASE CONTROL/COMMUNICABLE DISESES NETWORK AUSTRALIA NEW ZELAND: Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 1998. Commun. Dis. Intell. (2000) 24:1-4.
102. DAN M, POCH F, SHEINBERG B: High Prevalence of high-level ciprofloxacin resistance in N. gonorrhoeae in Tel Aviv, Israel: correlation with response to therapy. Antimicrob. Agents Chemother. (2002) 46:1671-1673.
103. DORLENCOURT F, BOIREUX C, SEDNAOUI P, DANIELENKO NV, LEGROS D: In vitro susceptibility of 120 strains of Neisseria gonorrhoeae isolated in Kyrghyzstan. Sex. Transm. Dis. (2002) 29:376-379.
104. FENTON KA, ISON C, JOHNSON AP et al.: Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales. Lancet (2003) 361:1867-1869.
105. NISSINEN A, JARVINEN H, LIIMATAINEN O, JAHKOLA M, HUOVINEN P: Antimicrobial resistance in Neisseria gonorrhoeae in Finland, 1976 to 1995. Sex. Transm. Dis. (1997) 24:576-581.
106. DRAGSTED D, POULSEN P, NORGAARD C, LIND I: Antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in Nuuk, Greenland during 1998-1999. Int. J. STD AIDS (2002) 13:826-828.
107. SEKHINE SV, STRATCHOUNSKI LS: Resistance to antibiotics in Neisseria gonorrhoeae in Russia: There is something to worry about. J. Antimicrob. Chemother. (1999) 44(Suppl. A):81.
108. ZENILMAN JM: Update on quinolone resistance in Neisseria gonorrhoeae. Curr. Infect. Dis. Rep. (2002) 4:144-147.
109. WANG SA, HARVEY AB, CONNER AM et al.: Gonococcal susceptibility and epidemiological trends: Data from the Gonococcal Isolate Surveillance Project, United States, 2002. Program and Abstracts of the 15th Annual Meeting of the International Society of Sexually Transmitted Disease Research, Ottawa, Ontario, Canada. July 27 - 30 (2003) Abstract 284.
110. LLANES R, SOSA J, GUZMAN D et al.: Antimicrobial susceptibility of Neisseria gonorrhoeae in Cuba (1995-1999): Implications for treatment of gonorrhea. Sex. Transm. Dis. (2003) 30:10-14.
111. LLANES R, ZAMORA A, NAPOLES M et al.: Antimicrobial resistance of Neisseria gonorrhoeae in the municipality of Moron, Cuba: emergence of isolates with intermediate resistance to fluoroquinolones. J. Antimicrob. Chemother. (2003) 51:191-192.
112. DILLON J-AR, LI H, SEALU J, RUBEN M, PRABHAKAR P: Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from three Caribbean countries: Trinidad, Guyana, and St. Vincent. Sex. Transm. Dis. (2001) 28:508-514.
113. FAMIGLIETTI A, GARCIA SD, DE MIER CA et al.: Evaluation of Neisseria gonorrhoeae drug susceptibility in Buenos Aires, Argentina, 1985-1999. Sex. Transm. Infect. (2001) 77:142.
114. MOODLEY P, STURM AW: Ciprofloxacin resistance in Neisseria gonorrhoeae. Lancet (2001) 357:1295-1296.
115. TAPSALL JW, LIMNIOS EA, SHULTZ TR: Continuing evolution of the pattern of quinolone resistance in N. gonorrhoeae isolated in Sydney, Australia. Sex. Transm. Dis. (1998) 25:415-417.
116. TOMPKINS JR, ZENILMAN JM: Quinolone resistance in Neisseria gonorrhoeae. Curr. Infec. Dis. Rep. (2001) 3:156-161.
117. KAM KM, LAI CF, EGGLESTONE S, CHAN CB: Pattern of antibiotic susceptibility of gonococci isolated in Hong Kong, 1987-1990. Sex. Transm. Dis. (1992) 19:284-287.
118. KAM K-M, LO K-K, NG K-Y-H, CHEUNG M-M: Rapid decline in penicillinase-producing Neisseria gonorrhoeae in Hong Kong associated with emerging 4-fluoroquinolone resistance. Genitourin. Med. (1995) 71:141-144.
119. ALPASCA DE LOS REYES MR, PATO-MESOLA V, KLAUSNER JD et al.: A randomised trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in the Philippines. Clin. Infec. Dis. (2001) 32:1313-1318.
120. YE S, SU X, WANG Q, YIN Y, DAI X, SUN H: Surveillance of antibiotic resistance of Neisseria gonorrhoeae isolates in China, 1993 - 1998. Sex. Transm. Dis. (2002) 29:242-245.
121. GU W, YANG Y, WU L, GAO Z, WANG H, LIAO M: Surveillance of antibiotic susceptibility of Neisseria gonorrhoeae in Shanghai:1988-2002. Program and Abstracts of the 15th Annual Meeting of the International Society of Sexually Transmitted Disease Research, Ottawa, Ontario, Canada. July 27 - 30 (2003) Abstract 99.
122. CHEN C, TUMPEY A, MIKA J et al.: High prevalence of ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Guangzhou, China. Program and Abstracts of the 15th Annual Meeting of the International Society of Sexually Transmitted Disease Research, Ottawa, Ontario, Canada. July 27 - 30 (2003) (Abstract 188).
123. CLENDENNEN TE, ECHEVERRIA P, SAENGEUR S, KEES ES, BOSLEGO JW, WIGNAIL FS: Antibiotic susceptibility survey of Neisseria gonorrhoeae in Thailand. Antimicrobial. Agents Chemother. (1992) 36:1682-1687.
124. LESMANA M, LEBRON CI, TASLIM D et al.: In vitro antibiotic susceptibility of Neisseria gonorrhoeae in Jakarta, Indonesia. Antimicrob. Agents Chemother. (2001) 45:359-362.
125. IEVEN M, VAN LOOVEREN M, SUDIGDOADI S et al.: Antimicrobial susceptibilities of Neisseria gonorrhoeae strains isolated in Java, Indonesia. Sex. Transm. Dis. (2003) 30:25-29.
126. SU X, HUTAPEA N, TAPSALL JW, LIND I: Plasmid mediated resistance of Neisseria gonorrhoeae strains isolated from female sex workers in North Sumatra, Indonesia, 1996. Sex. Transm. Dis. (2003) 30:178-182.
127. JOESOEF MR, KNAPP JS, IDAJANI A et al.: Antimicrobial susceptibilities of Neisseria gonorrhoeae strains in Surabaya, Indonesia. Antimicrob. Agents Chemother. (1994) 38:2530-2533.
128. DAN M, POCH F, SPITZ D, SHEINBERG B: High level ciprofloxacin resistance in N. gonorrhoeae: First report from Israel. Emerg. Infect. Dis. (2001) 7:158-159.
129. AL-HATTAWI K, ISON CA. Characteristics of gonococci isolated from men with urethritis in Dubai. Epidemiol. Infect. (1996)116:15-20.
130. ALCALA B, ARREAZA L, SALCEDO C et al.: Molecular characterization of ciprofloxacin resistance of gonococcal strains in Spain. Sex. Transm. Dis. (2003) 30:395-398.
131. WAGNER J, TEBBE B, HORNLE R et al.: Antibiotic susceptibility of Neisseria gonorrhoeae isolates in Berlin. Hautarzt (2000) 51:666-669.
132. ISON CA, BRANLEY NS, KIRKLAND K, EASMON CSF: Surveillance of antibiotic resistance in clinical isolates of Neisseria gonorrhoeae. Br. Med. J. (1991) 303:1307-1308.
133. ISON CA, MARTIN UMC: Gonorrhoea in London: usefulness of first line therapies. Sex. Transm. Infect. (2002) 78:106-109.
134. CORKILL JE, KOMOLAFE AJ, NEAL TJ, MORTIMORE A, ALLAWATTAGAMA AB, HART CA: Molecular epidemiology of endemic ciprofloxacin-resistant Neisseria gonorrhoeae in Liverpool. Int. J. STD AIDS (2003) 14:379-385.
135. LEWIS DA, BROOK MG, SHAFI MS: High level ciprofloxacin resistant gonorrhea imported from Russia. Genitourin. Med. (1997) 73:325-326.
136. EHRET JM, JUDSON FN: Quinolone-resistant Neisseria gonorrhoeae: The beginning of the end? Report of quinolone-resistant isolates and surveillance in the Southwestern United States, 1989 to 1997. Sex. Transm. Dis. (1998) 25:522-526.
137. GORWITZ RJ, NAKASHIMA AK, MORAN JS, KNAPP JS, and the GONOCOCCAL ISOLATE SURVEILLANCE PROJECT STUDY GROUP: Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae - United States, 1988-1991. Morbid. Mortal Weekly Rep. (1993) 42(Suppl. SS-3):29-39.
138. FOX KK, KNAPP JS, HOLMES KK et al.: Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988 - 1994: The emergence of decreased susceptibility to the fluoroquinolones. J. Infect. Dis. (1997) 175:1396-1403.
139. KNAPP JS, WASHINGTON JA, DOYLE IJ et al.: Persistence of Neisseria gonorrhoeae strains with reduced susceptibility to ciprofloxacin and ofloxacin in Cleveland, Ohio from 1992 through 1993. Antimicrob. Agents Chemother. (1994) 38:2194-2196.
140. KILMARX PH, KNAPP JS, XIA M et al.: Intercity spread of gonococci with decreased susceptibility to fluoroquinolones: A unique focus in the United States. J. Infect. Dis. (1998) 177:677-682.
141. KATZ AR, LEE MVC, OHYE RG, WHITICAR PM, EFFLER: Ciprofloxacin resistance in Neisseria gonorrhoeae: Trends in Hawaii, 1997 - 2002. Lancet (2003) 362:495.
142. CENTERS FOR DISEASE CONTROL AND PREVENTION: Fluoroquinolone-resistant Neisseria gonorrhoeae - San Diego, California, 1997. MMWR Morb. Mort. Wkly Rep. (1998) 47:405-408.
143. CENTERS FOR DISEASE CONTROL AND PREVENTION: Increase in fluoroquinolone- resistant Neisseria gonorrhoeae Hawaii and California, 2001. MMWR Morb. Mort. Wkly Rep. (2002) 51:1041-1044.
144. CENTERS FOR DISEASE CONTROL AND PREVENTION: Sexually transmitted disease surveillance 2001 supplement: Gonococcal Isolates Surveillance Project (GISP) annual report 2001. Atlanta, Georgia: US department of Health and Human Services, October, 2002.
145. CENTERS FOR DISEASE CONTROL AND PREVENTION: Sexually transmitted diseases treatment guidelines 2002. MMWR Morb. Mort. Wkly Rep. (2002) 51:1-78.
146. ZENILMAN J: Gonococcal susceptibility to antimicrobials in Baltimore, 1988-1994. Sex. Transm. Dis. (1996) 23:213-218.
147. LLANES R, SOSA J, GUZMAN D, GUTIERREZ Y, LLOP A, RICARDO O: Neisseria gonorrhoeae resistant to ciprofloxacin: First report in Cuba. Sex. Transm. Dis. (2001) 28:82-83.
148. SWANSTON WH, AI C, MAHABIR BS, PRABHAKAR P, BASRAJ S, GEORGE J: Antibiotic susceptibility of Neisseria gonorrhoeae in Trinidad and Tobago. West Indian Med. J. (1997) 46:107-110.
149. DILLON J-AR, RUBABAZA J-PA, SCHWARTZ BENZAKEN A et al.: Reduced susceptibility to azithromycin and high percentages of penicillin and tetracycline resistance in Neisseria gonorrhoeae isolates from Manaus, Brazil, 1998. Sex. Trans. Dis. (2001) 28:521-526.
150. FIORITO S, GALARZA P, PAGANO I et al.: Emergence of high level ciprofloxacin resistant Neisseria gonorrhoeae strain in Buenos Aires, Argentina. Sex. Transm. Infect. (2001) 77:77.
151. VAN DYKE E, KARITA E, ABDELLATI S et al.: Antimicrobial susceptibility of Neisseria gonorrhoeae in Kigali Rwanda, and trends of resistance between 1986 and 2000. Sex. Transm. Dis. (2001) 28:539-545.
152. OTUBU JAM, IMADE GE, SAGAY AS, TOWOBOLA OA: Resistance of recent Neisseria gonorrhoeae isolates in Nigeria and outcome of single-dose treatment with ciprofloxacin. Infection (1992) 20:339-341.
153. VAN DYKE E, CRABBE F, NZILA N et al.: Increasing resistance of Neisseria gonorrhoeae in west and central Africa. Consequences of therapy of gonococcal infection. Sex. Transm. Dis. (1997) 24:32-37.
154. ISON CA, ROOPE NS, DANGOR Y, RADEBE F, BALLARD R: Antimicrobial susceptibilities and serotyping of Neisseria gonorrhoeae in southern Africa: Influence of geographical source of infection. Epidemiol. Infect. (1993) 110:297-305.
155. WEST B, CHANGALUCHA J, GROSSKURTH H et al.: Antimicrobial susceptibility, auxotype and plasmid content of Neisseria gonorrhoeae in northern Tanzania: Emergence of high level plasmid mediated tetracycline resistance. Genitourin. Med. (1995) 71:9-12.
156. ISON CA, PEPIN J, DEMBA E, SECKA O, EASMON CS: The dominance of a multiresistant strain of Neisseria gonorrhoeae among prostitutes and STD patients in the Gambia. Genitourin. Med. (1992) 68:356-360.
157. ADEGBOLA RA, SABALLY S, CORRAH T, WEST B, MABEY D: Increasing prevalence of penicillinase-producing Neisseria gonorrhoeae and emergence of high-level, plasmid-mediated tetracycline resistance among gonococcal isolates in The Gambia. Trop. Med. Int. Health (1997) 2:428-432.
158. MASON PR, GWANZURA L, LATIF AS, MAROWA E, RAY S, KATZENSTEIN DA: Antimicrobial resistance in gonococci isolated from patients and from commercial sex workers in Harare, Zimbabwe. Int. J. Antimicrob. Agents (1997) 9:175-179.
159. GUYOT A, JARRETT B, SANVEE L, DORE D: Antimicrobial resistance of Neisseria gonorrhoeae in Liberia. Transact. Royal Soc. Trop. Med. Hyg. (1998) 92:670-674.
160. MOODLEY P, PILLAY C, GOGA R, KHARSANY BMA, STURM W: Evolution in the trends of antimicrobial resistance in Neisseria gonorrhoeae isolated in Durban over a 5 year period: Impact of the introduction of syndromic management. J. Antimicrob. Chemother. (2001) 48:853-859.
161. MBWANA J, MHALU F, MWAKAGILE D, MASESA J, MOSHIRO C, SANDSTORM E: Susceptibility pattern of Neisseria gonorrhoeae to antimicrobial agents in Dar es Salaam. East Afr. Med. J. (1999) 76:330-334.
162. RAHMAN M, ALAM A, NESSA K et al.: Treatment failure with the use of ciprofloxacin for gonorrhea correlates with the prevalence of fluoroquinolones-resistant Neisseria gonorrhoeae strains in Bangladesh. Clin. Infect. Dis. (2001) 32:884-889.
163. WOODFORD N, ISON CA: The effect of media on antimicrobial susceptibility testing of Neisseria gonorrhoeae. J. Antimicrob. Chemother. (1988) 22:463-471.
164. NG PP, CHAN RK, LING AE: Gonorrhea treatment failure and ciprofloxacin resistance. Int. J. STD AIDS (1998) 9:323-325.
165. KAM KM, LO KK, CHONG LY et al.: Correlation between in vitro quinolone susceptibility of Neisseria gonorrhoeae and outcome of treatment of gonococcal urethritis with single-dose ofloxacin. Clin. Infect. Dis. (1999) 28:1165-1166.
166. BOGAERT J, TELLO WM, AKINGENEYE J, MUKANTABANA V, VAN DYCK E, PIOT P: Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhea and decrease of in vitro susceptibility to quinolones over time in Rwanda. Genitourin. Med. (1993) 69:196-200.
167. CHOWDHRY S, PANDHI D, IDHANI S, BHALLA P, REDDY BS: High incidence of treatment failure of Neisseria gonorrhoeae isolates to ciprofloxacin in male gonococcal urethritis in Delhi. Int. J. STD AIDS (2002) 13:564-567.
168. ROY K, WANG S, MELTZER M: Identifying die optimal diagnostic and treatment strategy for gonorrhea in a time of increasing ciprofloxacin-resistance [Abstract]. In: Program and Abstracts of the 2002 Conference on Antimicrobial Resistance. Bethesda, Maryland, USA. National Foundation for Infectious Diseases. June 27 - 29 (2002).
169. AZNAR J, RODRIGUEZ-PICHARO A, HERNANDEZ I, DE MIGUEL C, PEREA EJ: Comparative clinical efficacy of two different single-dose ciprofloxacin treatments for uncomplicated gonorrhea. Sex. Transm. Dis. (1986) 13:169-171.
170. LOO PS, RIDGEWAY GL, ORIEL JD: Single dose ciprofloxacin for treating gonococcal infections in men. Genitourin. Med. (1985) 61; 302-305.
171. BELLI L, CASTRO JM, CASCO R: Ciprofloxacin in the treatment of noncomplicated gonococcal urethritis. In: Proceedings of the 14th International Congress of Chemotherapy, Kyoto, Japan. (1985):1687-1688
172. PEREA EJ, PRADOS R, DE MIGUEL C, AZNAR J: Single-dose ciprofloxacin treatment of gonococcal urethritis. Proc. Exc. Med. (1985) 34:338-341.
173. SHAHMANESH M, SKULKA SR, PHILLIP I, WESTWOOD A, THIN RN: Ciprofloxacin for treating urethral gonorrhea in men. Genitourin. Med. (1986) 62:86-87.
174. TEGELBERG-STASSEN MJAM, VAN DER HOEK JCS, MOOI L et al.: Treatment of uncomplicated gonococcal urethritis in men with two dosages of ciprofloxacin. Eur. J. Clin. Microbiol. (1986) 5:244-246.
175. DE L'EXPOSTO F, DUNCSN MO, DANGOR Y, FEHLER HG, LEIBOWITZ L, BALLARD FC: In vitro activity and clinical efficacy of ciprofloxacin for the treatment of gonorrhea and associated infections. Presented at the 15th International Congress of Chemotherapy, Istanbul, Turkey. July 19 - 24 (1987) Abstract 1201.
176. AVONTS D, FRANSEN L, VIELFOND J, STEVENS A, HENDRICKX K, PIOT P: Treating uncomplicated gonococcal infection with 250 mg or 100 mg ciprofloxacin in a single oral dose. Genitourin. Med. (1988) 64:134-137.
177. SHANMUGARATNAM K, SPROTT MS, PATTMAN RS, KEARNS AM, WATSON PG: Single dose ciprofloxacin to treat women with gonorrhea. Genitourin. Med. (1989) 65:129.
178. BALACHANDRAN T, ROBERTS AP, EVANS BA, AZADIAN BS: Single-dose therapy of anogenital and pharyngeal gonorrhea with ciprofloxacin. Int. J. STD AIDS (1992) 3:49-51.
179. RAJAKUMER MK, NGEOW YF, KHOR BS, LIM KF: Ofloxacin, a new quinolone for the treatment of gonorrhea. Sex. Transm. Dis. (1988) 15:25-26.
180. RICHMOND SJ, BHATTACHARYYA MN, MAITI H, CHOWHURY EH, STIRAND RM, TOOTH JA: The efficacy of ofloxacin against infection caused by Neisseria gonorrhoeae and Chlamydia trachomatis. J. Antimicrob. Chemother. (1988) 22(Suppl. C):149-153.
181. HEAP BJ: Low dose oral ofloxacin to treat gonorrhea in Hong Kong. Genitourin. Med. (1989) 65:198.
182. MAITI H, CHOWDHURY FH, RICHMOND SJ et al.: Ofloxacin in the treatment of uncomplicated gonorrhea and chlamydial genital infection. Clin. Ther. (1991) 13; 441-447.
183. SMITH BL, CUMMINGS MC, COVINO JM, BENES S, DRAFT K, MCCORMACK WM: Evaluation of ofloxacin in the treatment of uncomplicated gonorrhea. Sex. Transm. Dis. (1991) 18:18-20.
184. MATSUDA T, TAKEUCHI H, YOSHIDA O: Clinical efficacy of ofloxacin against male urethritis. Eur. J. Clin. Microbiol. Infect. Dis. (1991) Special Issue:311-312.
185. ZIEGLER C, STERY A, MAILER H, KOPP W, GEBHART W, SOLTZ-SZOTS J: Quinolones as an alternative treatment of chlamydial, Mycoplasma and gonococcal urogenital infections. Dermatology (1992) 185:128-131.
186. ROMANOWSKI B, WOOD H, DRAKER J, TSIANCO MC: Norfloxacin in the therapy of uncomplicated gonorrhea. Antimicrob. Agents Chemother. (1986) 30:514-515.
187. CRISTIANO P: Clinical trial of norfloxacin in the treatment of uncomplicated gonococcal urethritis: Preliminary report. Drugs Exp. Clin. Res. (1989) 15:33-35.
188. NOTOWICZ A, STOLLZ E, VAN KLINGERMAN B: A double blind study comparing two closes of enoxacin for the treatment of uncomplicated urogenital gonorrhea. J. Antimicrobiol. Chemother. (1984) 14(Suppl. C):91-94.
189. TEGELBERG-STASSEN MJ, VAN DER WILLIGEN AH, VAN DER HOEK JCS et al.: Treatment of uncomplicated gonorrhea in women with a single dose of enoxacin. Eur. J. Clin. Microbiol (1986) 5:395-398.
190. VANDER WILLIGEN AH, VAN DER HOEK JCS, WAGENVOORT JHT et al.: Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males. Antimicrobial. Agents Chemother. (1987) 31:535-538.
191. SIBOULET A, BOHBOT JM, CATALAN A: Enoxacin in the treatment of sexually transmitted diseases. J. Antimicrob. Chemother. (1988) 21 (Suppl. B):119-124.
192. SMITH BL, CUMMINGS M, BENES S, DRAFT K, MCCORMACK WM: Evaluation of difloxacin in the treatment of uncomplicated urethral gonorrhea in men. Antimicrob. Agents Chemother. (1989) 33:1721-1723.
193. HOOK EW, PINSON GB, BLALOCK CJ, JOHNSON RB: Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea. Antimicrob. Agents Chemother. (1996) 40:1720-1721.
194. RODDY RE, HANDSFIELD HH, HOOK EW: Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men. Antimicrob. Agents Chemother. (1986) 30:267-269.
195. SCOTT GR, MCMILLAN A, YOUNG H: Ciprofloxacin versus ampicillin and probenecid in the treatment of uncomplicated gonorrhea in men. J. Antimicrob. Chemother. (1987) 20:117-121.
196. BELLI I, CASTRO JM, CASTRO YR: Ciprofloxacin in the treatment of uncompAicated gonococcal urethritis. In: Ciprofloxacin: a new era in antibiotics. Arango JC, Bernardo FC, Belli I et al. (Eds) Schwer verlag GmbH, Stuttgart, Germany (1988):75-77.
197. LASSUS A, KARPPINEN L, INGERVO L et al.: Ciprofloxacin versus amoxicillin and probenecid in the treatment of uncomplicated gonorrhea. Scand. J. Infect. Dis. (1989) 60(Suppl):58-61.
198. TRAISUPA A: The role of ciprofloxacin in sexually transmitted diseases. Int. J. Clin. Pract. (1990) 6(Suppl. 1):47-50.
199. BRYAN JP, HIRA SK, BRADY W et al.: Oral ciprofloxacin versus ceftriaxone for the treatment of urethritis from resistant Neisseria gonorrhoeae in Zambia. Antimicrob. Agents Chemother. (1990) 34:819-822.
200. NDINYA-ACHOLA O, ODHIAMBO FA, WAMBUGU P et al.: Ciprofloxacin treatment of gonococcal infections. Proceedings of the 9th Meeting of the International Society for Sexually Transmitted Disease Research, Nairobi, Kenya (1991) Abstract P-20-258.
201. HOOK EW III, JONES RB, MARTIN DH et al.: Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women. Antimicrob. Agents Chemother. (1993) 37:1670-1673.
202. THORPE EW, SCHWEBKE JR, HOOK EW et al.: Comparison of single-dose cefuroxime axetil with ciprofloxacin in treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing Neisseria gonorrhoeae. Antimicrob. Agents Chemother. (1996) 40:2775-2780.
203. BOSLEGO JW, HICKS CB, GREENUP R et al.: A prospective randomised trial of ofloxacin versus doxycycline in the treatment of uncomplicated male urethritis. Sex. Transm. Dis. (1988) 15:186-191.
204. BLACK JH, LONG JM, ZWICKL BE, RAY BS et al.: Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection. Antimicrob. Agents Chemother. (1989) 33:167-170.
205. LUTZ FB Jr: Single-dose efficacy of ofloxacin in uncomplicated gonorrhea. Am. J. Med. (1989) 87:69S-74S.
206. COVINO JM, CUMMINGS M, SMITH B, BENES S, DRAFT K, MCCORMACK WM: Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase producing strains. Antimicrob. Agents Chemother. (1990) 34:148-149.
207. CRIDER SP, COLBY SD, MILLER LK, HARRISON WO, KERBS SB, BERG SW: Treatment of penicillin-resistant Neisseria gonorrhoeae with oral norfloxacin. N. Engl. J. Med. (1984) 311:137-140.
208. KAPLOWITZ LG, VISHNIASKY N, EVANS T et al.: Norfloxacin in the treatment of uncomplicated gonococcal infections. Am. J. Med. (1987) 82(6B):35-39.
209. BOGAERTS J, MARTINEZ TELLO W, VERBIST L, PIOT P, VENDEPITTE J: Norfloxacin versus thiamphenicol for treatment of uncomplicated gonorrhea in Rwanda. Antimicrob. Agents Chemother. (1987) 31:434-437.
210. PANIKABUTRA K, LEE CT, HO B, BAMBERG P: Single dose oral norfloxacin or intramuscular spectinomycin to treat gonorrhea (PPNG and non-PPNG infections): Analysis of efficacy and patient preference. Genitourin. Med. (1988) 64:235-240.
211. TIO TT, SINDHUMATA IR, WAGENVOORT JHT et al.: Pefloxacin compared with cefotaxime for treating men with uncomplicated gonococcal urethritis. J. Antimicrob. Chemother. (1990) 22(Suppl. B):141-146.
212. CHEONG LL, CHAN RK, NADARAJAH M: Pefloxacin and ciprofloxacin in the treatment of uncomplicated gonococcal urethritis in males. Genitourin. Med. (1992) 68:260-262.
213. LEOW YR, CHAN RK, CHEONG LL, GOH CL, NADARAJAH M: Comparing the efficacy of pefloxacin and ciprofloxacin in the treatment of acute uncomplicated gonococcal urethritis in males. Ann. Acad. Med. Singapore. (1995) 24:515-518.
214. PABST KM, SIEGEL NA, SMITH S, BLACK JR, HANDSFIELD HH, HOOK EW III: Multcentre comparative study of enoxacin and ceftriaxone for treatment of uncomplicated gonorrhea. Sex. Transm. Dis. (1989) 16:148-151.
215. ALBRECHT LM, RYBAK MJ, SCHUBINER, WEINER LM: Single dose enoxacin for the treatment of uncomplicated urogenital gonorrhea. Sex. Transm. Dis. (1989) 16:114-117.
216. COVINO JM, SMITH BL, CUMMINGS MC, BENES S, DRAFT K, MCCORMACK WM: Comparison of enoxacin and ceftriaxone in the treatment of uncomplicated gonorrhea. Sex. Transm. Dis. (1993) 20:227-229.
217. LASSUS A, ABATH FILHO L, SANTOS JUNIOR MF, BELLI L: Comparison of Fleroxacin and penicillin G plus probenecid in the treatment of acute uncomplicated gonococcal infections. Genitourin. Med. (1992) 68:317-320.
218. SMITH BL, MOGABGAB WJ, DALU Z et al.: Multicenter trial of Fleroxacin versus ceftriaxone in the treatment of uncomplicated gonorrhea. Am. J. Med. (1993) 94(3A):81S-84S.
219. MOGABGAB W, BUNTIN DM: Single-dose therapy of uncomplicated gonococcal urethritis or cervicitis: Oral temafloxacin versus intramuscular ceftriaxone. Eur. J. Am. Microbiol. Infect. Dis. (1991) Special Issue:205-206.
220. MOI H, MOREL P, GIANOTTI B, BARLOW D, PHILLIPS I, JEAN C: Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men. J. Antimicrob. Chemother. (1996) 37(Suppl. A):115-122.
221. JONES RB, SCHWEBKE J, THORPE EM, DALU ZA, LEONE P, JOHNSON RB: Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Trovafloxacin Gonorrhea Study Group. Am. J. Med. (1998) 104:28-32.
222. STONER BP, DOUGLAS JM, MARTIN DH et al.: Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: A randomized, double-blind, Multicenter trial. Sex. Transm. Dis. (2001) 28:136-142.
223. COKER DM, AHMED-JUSHUF I, ARYA OP, CHESSBROUGH JS, PRATT BC: Evaluation of single dose ciprofloxacin in the treatment of rectal and pharyngeal gonorrhea. J. Antimicrob. Chemother. (1989) 24:271-272.
224. BAKHTIAR M, SAMARASINGHE PL: Enoxacin as one day oral treatment of men with anal or pharyngeal gonorrhea. Genitourin. Med. (1988) 64:364-366.
225. ROMANOWSKI B, HARDY JS, RAFTER MS, DRAKER J: Enoxacin in the therapy of anal and pharyngeal gonococcal infections. Sex. Transm. Dis. (1989) 16:190-191.
226. CORRADO ML: The clinical experience with ofloxacin in the treatment in sexually transmitted diseases. Obstet. Gynecol. (1991) 164:1396-1399.
227. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Performance standards for antimicrobial susceptibility testing. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, PA, USA (2002) 22:53-55.
228. GUOMING L, QUN C, SHENGCHUN W: Resistance of Neisseria gonorrhoeae epidemic strains to antibiotics: Report of resistant isolates and surveillance in Zhanjiang, China: 1998 to 1999. Sex. Transm. Dis. (2000) 27:115-118.
229. ABEYEWICKEREME I, SENARATNE L, PRITHIVIRAJ VB: Rapid emergence of 4-fluoroquinolone resistance with associated decline in penicillinase-producing Neisseria gonorrhoeae in Colombo, Sri Lanka. Genitourin. Med. (1996) 72:302.
230. ISON CA, MARTIN IM: Susceptibility of gonococci isolated in London to therapeutic antibiotics: Establishment of a London surveillance programme. London Gonococcal Working Group. Sex. Transm. Infect. (1999) 75:107-111.
231. HOOK EW 3rd, MCCORMACK WM, MARTIN D, JONES RB, BEAN Y, MAROLI AN: Comparison of single-dose grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men, The STD Study Group. Antimicrob. Agents Chemother. (1997) 41:1843-1845.
232. WORLD HEALTH ORGANIZATION: Management of sexually transmitted diseases. WHO/UNAIDS (1997) WHO/GPA/94.1 Rev.1.